In antibody drug development, Fc fragment-mediated effector functions (such as ADCC and CDC) directly influence the drug's in vivo activity and efficacy. Therefore, accurate detection of the Fcγ fragment of IgG is not only a key indicator for evaluating drug quality but also fundamental for pharmacodynamic, pharmacokinetic, and immunogenicity studies. However, traditional antibody detection methods often result in high background signals and difficult data interpretation due to Fc cross-reactivity or non-specific binding.
AlpVHHs Anti-Human IgG (Fcγ Fragment specific) series of antibodies, specifically designed for the Human IgG Fcγ fragment, provides a powerful tool for antibody drug development with its high specificity and sensitivity.
This product series is specifically designed for Human IgG Fcγ fragments and has undergone rigorous cross-reactivity validation to ensure identification of only the target region, significantly improving the authenticity and reliability of detection data.
It offers multiple labeling formats, including HRP, Biotin, PE, APC, iFluor488, iFluor594, and iFluor647, and can be widely used for precise quantitative detection on platforms such as ELISA, WB, Flow Cyt, ICC/IF, and IP, meeting the needs of different experimental platforms and application scenarios.
Utilizing advanced recombinant antibody technology and optimized expression systems, the product exhibits high batch-to-batch consistency and stable activity. After rigorous thermostability testing, it maintains good performance even at 37°C, ensuring experimental results after long-term storage and transportation.
(1) Comparison of monoclonal antibody competitors: high signal-to-noise ratio, low background
Flow cytometry results showed that Anti-Human IgG (Fcγ Fragment specific) and AlpSdAbs VHH (APC) (Code: 023-101-011) had higher fluorescence intensity than imported brands at all concentration points, with stronger signals and significantly improved signal-to-noise ratio.
(2) Comparative verification of different batches of products
Flow cytometry analysis was performed on two independent batches of Anti-Human IgG (Fcγ Fragment specific), AlpSdAbs VHH (APC) (Code: 023-101-011). The results showed that the signals of different batches of products were highly overlapping, indicating that the product manufacturing process was stable, the consistency between batches was good, and the experimental results were highly reproducible.
(3) Accelerated stabilization test at 37℃
Flow cytometry results showed that Anti-Human IgG (Fcγ Fragment specific), AlpSdAbs VHH (APC) (Code: 023-101-011) showed a high degree of consistency with the signal of the 4℃ storage group after being placed at 37℃ for one month, indicating that the product has excellent thermal stability.
(1) Comparison of monoclonal antibody competitors: high signal-to-noise ratio, low background
Flow cytometry results showed that Anti-Human IgG (Fcγ Fragment specific), AlpSdAbs VHH(PE) (Code: 023-101-010) had higher fluorescence intensity than imported brands at all concentration points, with stronger signals and significantly improved signal-to-noise ratio.
(2) Comparative verification of different batches of products
Flow cytometry analysis was performed on two independent batches of Anti-Human IgG (Fcγ Fragment specific), AlpSdAbs VHH(PE) (Code: 023-101-010). The results showed that the signal curves of different batches of products highly overlapped, indicating that the product manufacturing process was stable, the consistency between batches was good, and the experimental results were highly reproducible.
(3) Accelerated stabilization test at 37℃
Flow cytometry results showed that Anti-Human IgG (Fcγ Fragment specific), AlpSdAbs VHH(PE) (Code: 023-101-010) showed a high degree of consistency with the signal of the 4℃ storage group after being placed at 37℃ for one month, indicating that the product has excellent thermal stability.
AlpVHHs Anti-Human IgG (Fcγ Fragment specific) series of nano-secondary antibody successfully addresses the long-standing pain points of traditional detection tools in terms of specificity and signal-to-noise ratio, based on our precise Fcγ fragment recognition, ultra-low background interference, and excellent thermal stability. This series not only significantly improves the quality of detection data in antibody drug development but also provides robust and reliable tool support for the rapid screening, efficacy evaluation, and quality control of innovative drugs. Thank you for your continued attention. AlpVHHs looks forward to working with you to jointly propel antibody drug development into a new era of greater precision and efficiency!
